Literature DB >> 28331462

A Case of Malignant Pheochromocytoma Presenting 7 Years After the Initial Surgery.

Larsa Al-Omaishi1, Jonathan Babin2, Ralph L Corsetti3.   

Abstract

BACKGROUND: Pheochromocytoma (PHEO) is a rare tumor of the adrenal medulla and sympathetic ganglion that produces the catecholamines norepinephrine and epinephrine. Traditionally, approximately 10% of PHEOs were thought to be malignant, but recent developments in PHEO research have noted that specific genetic mutations are associated with higher risk of metastatic spread. CASE REPORT: We report the case of a 71-year-old female who presented with abdominal pain in September 2009 when she was 64 years old. Evaluation at that time revealed cholelithiasis and bilateral adrenal masses. Workup showed elevated free normetanephrines, and positron emission tomography-computed tomography demonstrated bilateral adrenal hypermetabolic lesions concerning for malignancy. She underwent open bilateral adrenalectomies and cholecystectomy. The right adrenal mass was identified as a PHEO with nonaggressive features and negative margins, and the left adrenal mass was an adrenal cortical adenoma without dysplasia. In April 2016, the patient was referred by her endocrinologist for elevated blood pressure and 16-lb weight loss. The patient reported weakness, headaches, hot flashes, cold sweats, and fatigue. Laboratory workup revealed elevated plasma free normetanephrine, and imaging showed a recurrence of the PHEO in both the right adrenal bed and the head of the right humerus.
CONCLUSION: Current predictors of PHEO recurrence failed to identify the original tumor as aggressive or likely to return as a metastatic lesion. Because of the rarity of these tumors, few consistent laboratory or radiologic predictors of malignancy based on initial presentation have been identified; predictors of malignancy in PHEO warrant further investigation.

Entities:  

Keywords:  3-Iodobenzylguanidine; neuroendocrine tumors; pheochromocytoma

Year:  2017        PMID: 28331462      PMCID: PMC5349626     

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  17 in total

1.  Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas.

Authors:  L Castilla-Guerra; A M Moreno; M C Fernández-Moreno; J C Utrilla; E Fernández; H Galera-Davison
Journal:  Histopathology       Date:  1997-08       Impact factor: 5.087

Review 2.  Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor.

Authors:  Elisabeth Edström Elder; Grahame Elder; Catharina Larsson
Journal:  J Surg Oncol       Date:  2005-03-01       Impact factor: 3.454

3.  Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas.

Authors:  R R de Krijger; E van der Harst; F van der Ham; T Stijnen; W N Dinjens; J W Koper; H A Bruining; S W Lamberts; F T Bosman
Journal:  J Pathol       Date:  1999-05       Impact factor: 7.996

4.  Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.

Authors:  Montserrat Ayala-Ramirez; Lei Feng; Marcella M Johnson; Shamim Ejaz; Mouhammed Amir Habra; Thereasa Rich; Naifa Busaidy; Gilbert J Cote; Nancy Perrier; Alexandria Phan; Shreyaskumar Patel; Steven Waguespack; Camilo Jimenez
Journal:  J Clin Endocrinol Metab       Date:  2010-12-29       Impact factor: 5.958

5.  Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas.

Authors:  Baohua Gao; Fanwei Meng; Wei Bian; Jun Chen; Haifeng Zhao; Gang Ma; Benkang Shi; Jianping Zhang; Yuqiang Liu; Zhishun Xu
Journal:  Urology       Date:  2006-08       Impact factor: 2.649

6.  Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.

Authors:  D Gupta; V Shidham; J Holden; L Layfield
Journal:  Appl Immunohistochem Mol Morphol       Date:  2000-12

7.  Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.

Authors:  Lester D R Thompson
Journal:  Am J Surg Pathol       Date:  2002-05       Impact factor: 6.394

8.  Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score.

Authors:  David Wu; Arthur S Tischler; Ricardo V Lloyd; Ronald A DeLellis; Ronald de Krijger; Francien van Nederveen; Vânia Nosé
Journal:  Am J Surg Pathol       Date:  2009-04       Impact factor: 6.394

9.  Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.

Authors:  Vivian E Strong; Timothy Kennedy; Hikmat Al-Ahmadie; Laura Tang; Jonathan Coleman; Yuman Fong; Murray Brennan; Ronald A Ghossein
Journal:  Surgery       Date:  2008-04-14       Impact factor: 3.982

10.  Adrenal pheochromocytoma: a clinicopathologic review of 60 cases.

Authors:  L J Medeiros; B C Wolf; K Balogh; M Federman
Journal:  Hum Pathol       Date:  1985-06       Impact factor: 3.466

View more
  1 in total

1.  Diabetes Mellitus and Cardiomyopathy as Presenting Features of Occult Malignant Pheochromocytoma.

Authors:  Piti Inthaphan; Worapaka Manosroi; Puwitch Charoenchue; Komson Wannasai
Journal:  Cureus       Date:  2021-11-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.